Drug Trial Radar · NCT05583552
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jun 5, 2023
Primary completion
Mar 27, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- GCP-Service International West GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Geron Corporation; Universitätsklinikum Leipzig; Saint-Louis Hospital, Paris, France; QIMR Berghofer Medical Research Institute; Australasian Leukaemia and Lymphoma Group; Groupe Francophone des Myelodysplasies; German Myelodysplastic Syndrome Study Group
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.
Conditions
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
Interventions
Imetelstat sodiumDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Hematological Response Rate of Participants After Treatment With ImetelstatTime frame: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Royal Adelaide Hospital
Adelaide, Australia
Royal Brisbane and Women's Hospitals
Brisbane, Australia
Linear Clinical Research
Nedlands, Australia
CHU Nantes - Hôtel Dieu
Nantes, France
Hôpital Archet 1
Nice, France
Hôpital Saint-Louis
Paris, France
CHU de Toulouse
Toulouse, France
Marien Hospital Düsseldorf
Düsseldorf, Germany
Universität Jena, Medizinische Fakultät
Jena, Germany
Universität Leipzig, Medizinische Fakultät
Leipzig, Germany
Klinikum rechts der Isar
München, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.